Status:
COMPLETED
A 52-Week Placebo-Controlled Study Evaluating the Safety of Varenicline
Lead Sponsor:
Pfizer
Conditions:
Smoking Cessation
Eligibility:
All Genders
18-75 years
Phase:
PHASE3
Brief Summary
The primary purpose of this study is to obtain safety information on cigarette smokers treated with 52 weeks of varenicline regardless of smoking status.
Eligibility Criteria
Inclusion
- Subjects must have smoked an average of at least 10 cigarettes per day during the past year and over the month prior to the screening visit, with no period of abstinence greater than 3 months in the past year.
Exclusion
- Subjects with clinically significant, recent cardiovascular disease.
Key Trial Info
Start Date :
October 1 2003
Trial Type :
INTERVENTIONAL
End Date :
March 1 2005
Estimated Enrollment :
375 Patients enrolled
Trial Details
Trial ID
NCT00143299
Start Date
October 1 2003
End Date
March 1 2005
Last Update
June 4 2007
Active Locations (9)
Enter a location and click search to find clinical trials sorted by distance.
1
Pfizer Investigational Site
Denver, Colorado, United States, 80212
2
Pfizer Investigational Site
Milford, Massachusetts, United States, 01757
3
Pfizer Investigational Site
Albuquerque, New Mexico, United States, 87108
4
Pfizer Investigational Site
Syracuse, New York, United States, 13210